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Liver biopsy has been referred to as the gold standard for the 
diagnosis of liver diseases and evaluation of liver fibrosis or liver 
damage. The American Association for the Study of Liver Disease 
guidelines have suggested the following indications for liver biop-
sy,1 namely, diagnosis of parenchymal liver diseases, abnormal liv-
er function tests of uncertain causes, fever of unknown origin, 
and abnormal findings on imaging studies; staging of parenchy-
mal liver diseases; and development of treatment plans based on 
histopathologic findings. Among all indications for liver biopsy, its 
use in diagnosis is of utmost importance. For example, histologi-
cal findings of interface hepatitis and lymphoplasmacytic infil-
trates in portal tract are seen in autoimmune hepatitis,2 and de-
struction of the interlobular bile duct and nonsuppurative 
destructive cholangitis are observed in primary biliary cholangitis.3 
Liver biopsy plays an important role in the diagnosis of malignan-
cies, such as hepatocellular carcinoma, which can also be diag-
nosed by typical imaging findings in multiphasic computed to-
mography (CT) or magnetic resonance imaging (MRI) in patients 
with risk factors, such as cirrhosis or chronic viral hepatitis. How-
ever, liver biopsy should be considered in patients who show typi-
cal image findings but do not have risk factors as well as in those 
who have risk factors but do not show typical image findings.4
Limitations to liver biopsy include invasive nature with possibili-
ty of complications, sampling variability and the subjective nature 
of the pathologist interpretation.5 Therefore, non-invasive meth-
ods have recently replaced or supplemented a significant portion 
of liver biopsy. As non-invasive tests, the scoring systems using 
serologic test such as fibrosis-4 (FIB-4) index, non-alcoholic fatty 
liver disease (NAFLD) fibrosis score, or aspartate transaminase to 
platelet ratio index (APRI) might be useful to screen advanced fi-
brosis or cirrhosis. These methods are easily obtained at no addi-
tional cost. Patients suspected of cirrhosis in these scoring sys-
tems might be confirmed without liver biopsy by imaging based 
non-invasive methods such as ultrasonography based elastogra-
phy such as transient elastography and two-dimensional shear 
wave elastography, and magnetic resonance elastography.
In the current study, the changes in indications for liver biopsy 
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in a single Korean tertiary care center were evaluated.6 In general, 
conducting liver biopsies for viral hepatitis has been found to de-
crease over time. This finding suggested the development of non-
invasive methods replacing the reported indications of liver biopsy 
for fibrosis staging in viral hepatitis. Transient elastography is the 
most widely used non-invasive method in the tertiary care center, 
and has been validated for the evaluation of liver fibrosis in vari-
ous liver diseases.7 Filtering out chronic hepatitis B patients with 
advanced fibrosis or cirrhosis is very important to determine the 
antiviral therapy or evaluate prognosis because current guidelines 
generally recommend antiviral therapy in patients with cirrhosis 
regardless of alanine transaminase levels,8-10 and thus, non-inva-
sive test methods can be very beneficial in determining antiviral 
therapy without a liver biopsy. In addition, the results of transient 
elastography on the degree of fibrosis can predict hepatocellular 
carcinoma risk in patients with chronic hepatitis B.11,12 However, 
the degree of liver stiffness from transient elastography can be 
overestimated in case of severe inflammation of liver,13 and the 
measurement of fibrosis may be difficult in patients with obesity 
or ascites. Therefore, it should be interpreted in consideration of 
various situations. Similar to viral hepatitis, liver biopsies for ma-
lignancy were also decreased over time in the current study,6 and 
it seems to be possible to diagnose hepatocellular carcinoma in 
most patients who have risk factors such as viral hepatitis or cir-
rhosis without liver biopsy due to the development of CT or MRI 
techniques.
However, in the current study, liver biopsies for autoimmune 
hepatitis or primary biliary cholangitis were increased.6 Although 
various serologic markers may suspect autoimmune hepatitis, but 
most cases are confirmed by liver biopsy.2 For primary biliary chol-
angitis, liver biopsy is especially helpful when anti-mitochondrial 
antibody is negative, or overlap syndrome with autoimmune hep-
atitis is suspected.3 In primary sclerosing cholangitis, “onion skin” 
can be observed in the biopsy sample. These pathological findings 
cannot be replaced by non-invasive tests. Non-invasive tests are 
helpful in NAFLD–transient elastography can measure not only fi-
brosis but also steatosis by controlled attenuated parameter. De-
spite the availability of non-invasive methods in the current study, 
liver biopsies for NAFLD also showed an increased pattern.6 This 
could have been due to an increased incidence of NAFLD, includ-
ing non-alcoholic steatohepatitis (NASH) in recent years. A liver 
biopsy is considered as an important test if the degree of steato-
hepatitis or NAFLD activity score (NAS) needs to be determined 
because there has been no proven non-invasive test that reflects 
the degree of inflammation and fibrosis in NASH. A liver biopsy 
also provides us useful informations when the cause of hepatitis 
is not clear. There is no alternative method or test that can replace 
liver biopsy for demonstrating the actual status of liver disease.
Percutaneous liver biopsy is the most widely used approach and 
is currently performed under ultrasonographic guidance. Conduct-
ing liver biopsy under guidance from ultrasonography has reduced 
the risk of complications.1 Two retrospective studies reported that 
major adverse events after percutaneous liver biopsies were about 
1.0%.14,15 Pain was the most common post-biopsy complication 
that occurred in 30–50% of the patients,16 but was not usually 
serious. Bleeding was the most common serious complication re-
ported to occur in 0.6% of the patients.14 Rare complications of 
organ injury, such as pneumothorax, hemothorax, or bile peritoni-
tis have also been reported.1 The outcomes in the current study 
showed a comparatively lower incidence of major adverse events 
(0.05%) than previous studies.6 This study included patients with 
advanced cirrhosis and ascites belonging to Child-Pugh Class B or 
C. Study results suggested that ultrasonography-guided percuta-
neous liver biopsies were performed without serious complica-
tions in most patients, including advanced cirrhosis; however, this 
study did not record whether patients with advanced cirrhosis had 
any bleeding tendency, such as thrombocytopenia or prolongation 
of prothrombin time. Therefore, in cirrhotic patients with bleeding 
tendency, other approaches, such as transjugular liver biopsy 
should be considered.
Although various non-invasive methods have been developed 
and are currently available, liver biopsy has its own irreplaceable 
role and is still important. The indication of liver biopsy has been 
changed from assessment of fibrosis in viral hepatitis to diagnosis 
of autoimmune hepatitis, primary biliary cirrhosis, and NASH 
mainly due to the changes in disease incidence as well as due to 
the development of non-invasive test. A liver biopsy can be safely 
performed in most patients, and therefore, should be always con-
sidered, if necessary. 
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